6 research outputs found
A POSSIBLE SCREENING-TEST FOR INHERITED P53-RELATED DEFECTS BASED ON THE APOPTOTIC RESPONSE OF PERIPHERAL-BLOOD LYMPHOCYTES TO DNA-DAMAGE
No full textHormonal Regulation of Sexually Differentiated Isozymes of Cytochrome P-450 in Rat Liver
No full textApoptosis, ageing and cancer susceptibility
No full textWe have previously shown that peripheral blood lymphocytes (PBL) from individuals carrying a germline TP53 mutation show a dramatically reduced apoptotic response to radiation. As part of a study of this phenomenon, we also investigated apoptotic response in a series of breast cancer patients lacking TP53 mutations and in a control group of individuals without cancer. There was a significant reduction in mean apoptotic response with increasing age in all groups. These findings are consistent with a number of studies in rodents, which have demonstrated a reduction in DNA damage-induced apoptosis with increasing age. In addition, after adjusting for age, breast cancer patients showed significantly reduced apoptotic responses compared with normal controls (P=0.002). The odds ratio for breast cancer in women with an apoptotic response of <35%, compared with women with a response of >49%, was 6.42 (95% CI 1.68-24.6). The data further support the hypothesis that a reduction in apoptotic response to DNA damage with increasing age may play a significant role in the age-related increase in cancer
REGULATION OF HEPATIC CYTOCHROME P-450 BY A NOVEL CONTROL SYSTEM, THE HYPOTHALAMO-PITUITARY-LIVER AXIS
No full textA.C. Petty, G.L. Daniels and P. Tippett, Vox Sang, 66, 216-224 (1994). 11. K.E. Coyne, S.E. Hall, E.S. Thompson, M.A. Arce, T. Kinoshita, T. Fujita, D.J. Anstee, W. Rosse and D.M. Lublin, J. Immun. 149. 2906-2913 (1992). 12. A.C. Petty, G.L. Daniels, D.J. Anstee and P. Tippett, Vox Sang., 65, 309-315 (1993). 13. M.J. Telen, N. Rao, E.S. Thompson and D.M. Lublin, (abs) Transfusion, 32, suppl 47S (1992). 14. G. Daniels, Vox Sang., 56, 205-211 (1989). 15. M.J. Telen, in Blood Groups:Ch/Rq. Kn/McC/Yk, Cromer. J.M. Moulds and B. Laird-Fryer, eds. American Association of Blood Banks, Bethesda MD, (1992) pp. 45-63. 16. D.M. Lublin, E.S. Thompson, A.M. Green, C. Levene and M.J. Telen, J. Clin. Invest., 87, 1945-1952 (1991). 17. D.M. Lublin, G. Mallinson, M.E. Reid, J. Poole, E.S. Thompson, B.R. Ferdman, M.J. Telen, D.J. Anstee and M.J.A. Tanner, (abs) Transfusion, 32, suppl 47S (1992). 18. P.D. Issitt, Transf. Med. Rev., 3, 1-12 (1989). 19. C. Lomas, W. Grassman, D. Ford, J. Watt, A. Gooch, J. Jones, M. Beolet, D. Stern, M. Wallace and P. Tippett, Transfusion in press. 20. P. Agre and J-P. Cartron, Blood, 78, 551-563 (1991). 21. J-P. Cartron and P. Agre, Seminars Haemat., 30, 193-208 (1993). 22. D.J. Anstee and M.J.A. Tanner, in Baillieres’s Clinical Haematology. M.J.A. Tanner and D.J. Anstee, eds. Bailliere Tindall, London (1993) pp. 401-422. 23. N.D. Avent, K. Ridgwell, W.J. Mawby, M.J.A. Tanner, D.J. Anstee and B. Kumpel, Biochem. J., 256 1043-1046 (1988). 24. C. Bloy, D. Blanchard, W. Dahr, K. Beyreuther, C. Salmon and J-P. Cartron, Blood, 72, 661-666 (1988). 25. A.M. Saboori, B.L. Smith and P. Agre, Proc. Natl. Acad. Sci. USA, 85, 4042-4045 (1988). 26. N.D. Avent, K. Ridgwell, M.J.A. Tanner and D.J. Anstee, Biochem. J., 271.821-825 (1990). 27. B. Cherif-Zahar, C. Bloy, C. Le Van Kim, D. Blanchard, P. Bailly, P. Hermand, C. Salmon, J-P. Cartron, Y. Colin, Proc. Natl. Acad. Sci. USA, 87, 6243-6247 (1990). 28. I. Mouro, Y. Colin, B. Cherif-Zahar, J-P. Cartron and C. Le Van Kim, Nature Genet., 5, 62-65 (1993). 29. K. Ridgwell, N.K. Spurr, B. Laguda, C. MacGeoch, N.D. Avent and M.J.A. Tanner, Biochem. J., 287, 223-228 (1992). 30. G. Mallinson, D.J. Anstee, N.D. Avent, K. Ridgwell, M.J.A. Tanner, G.L. Daniels, P. Tippett and A.E.G. von dem Borne, Transfusion, 30, 222-225 (1990).
No full textФармакокинетические взаимодействия лекарственных веществ, метаболизируемых изоферментом цитохрома P450 CYP2C9
No full textThe role of cytochrome P450 isoforms CYP2C9 and in the metabolism of losartan described. Losartan pharmacokinetics data in humans and laboratory animals are presented. Examples of drug-drug interactions of substrate marker losartan of CYP2C9 of with different drugs are given. The results of studies of the effects of afobazole, an inducer (rifampicin) and inhibitors (fluconazole) in effective doses on the pharmacokinetics of losartan.Описана роль цитохрома Р450 и его изоформы CYP2C9 в метаболизме лозартана. Представлены данные о фармакокинетики лозартана у лабораторных животных и человека. Описаны примеры межлекарственного взаимодействия субстратного маркера CYP2C9 - лозартана с различными лекарственными веществами. Приведены результаты исследования влияния афобазола, индуктора (рифампицина) и ингибитора (флуконазола) в эффективных дозах на фармакокинетику лозартана
